SAA2 and obesity disorder: In a small study in which subjects with overweight or obesity were given rosiglitazone for 12 weeks, circulating SAA levels were reduced by 37% despite the absence of weight loss, and WAT explants from these subjects showed lower SAA secretion post-treatment (9).